Evidence map›Paper›PMID 34768648›Full record

ReviewJournal of clinical medicine2021

Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.

Dimitrios A Vrachatis, Konstantinos A Papathanasiou, Sotiria G Giotaki, Konstantinos Raisakis, Charalampos Kossyvakis, Andreas Kaoukis, Fotis Kolokathis, Gerasimos Deftereos, Konstantinos E Iliodromitis, Dimitrios Avramides and 7 more

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Medicina (Kaunas, Lithuania) · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 5 countries.

Dimitrios A VrachatisMedical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-2385-5365
Konstantinos A PapathanasiouMedical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0003-0123-2615
Sotiria G GiotakiMedical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Konstantinos RaisakisDepartment of Cardiology, "G. Gennimatas" General Hospital of Athens, 11527 Athens, Greece.
Charalampos KossyvakisDepartment of Cardiology, "G. Gennimatas" General Hospital of Athens, 11527 Athens, Greece.
Andreas KaoukisDepartment of Cardiology, "G. Gennimatas" General Hospital of Athens, 11527 Athens, Greece.
Fotis KolokathisMedical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Gerasimos DeftereosDepartment of Cardiology, "G. Gennimatas" General Hospital of Athens, 11527 Athens, Greece.
Konstantinos E IliodromitisEvangelisches Krankenhaus Hagen-Haspe, Clinic for Cardiology and Electrophysiology, 58135 Hagen, Germany.
Dimitrios AvramidesDepartment of Cardiology, "G. Gennimatas" General Hospital of Athens, 11527 Athens, Greece.
Harilaos BogossianEvangelisches Krankenhaus Hagen-Haspe, Clinic for Cardiology and Electrophysiology, 58135 Hagen, Germany.
Gerasimos SiasosMedical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
George GiannopoulosMedical School, Artistotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Bernhard ReimersHumanitas Research Hospital IRCCS, Rozzano, 20089 Milan, Italy.
Alexandra LanskySection of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA.
Jean-Claude TardifMontreal Heart Institute, Université de Montréal, Montreal, QC H1T 1C8, Canada.
Spyridon DeftereosMedical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
National and Kapodistrian University of Athens · GRGeneral Hospital of Athens G. Genimatas · GRWitten/Herdecke University · DEAristotle University of Thessaloniki · GRIRCCS Humanitas Research Hospital · ITMontreal Heart Institute · CAYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

In 2020, SARS-COV-2 put health systems under unprecedented resource and manpower pressure leading to significant number of deaths. Expectedly, researchers sought to shed light on the pathophysiologic background of this novel disease (COVID-19) as well as to facilitate the design of effective therapeutic modalities. Indeed, early enough the pivotal role of inflammatory and thrombotic pathways in SARS-COV-2 infection has been illustrated. The purpose of this article is to briefly present the epidemiologic and clinical features of COVID-19, analyze the pathophysiologic importance of immunologic dysregulation and hypercoagulability in developing disease complications and finally to present an up-to-date systematic review of colchicine's immunomodulating capacity in view of hindering coronavirus complications.

Indexed as

cardioprotectioncolchicineCOVID-19cytokine release syndromehypercoagulability

Identifiers

PMID34768648
PMCPMC8584586
OpenAlexW3210232679

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.